Study of Alfvén eigenmode stability in Quasi-Poloidal Stellarator (QPS) plasma using a Landau closure model

The aim of this study is to analyze the linear stability of Alfvén eigenmodes (AE) in the QPS device heated by a tangential neutral beam injector (NBI). The analysis is performed using the gyro-fluid code FAR3d, that solves the reduced MHD equations for the thermal plasma coupled with moments of the kinetic equation for the energetic particles (EP). The AE stability is calculated in several operational regimes of the tangential NBI: EP β between 0.001 and 0.1, EP energy between 12 and 180 keV and different radial locations of the beam. The analysis is performed for vacuum and finite β equilibria as well as QPS configurations with two and three periods. The EP β threshold in the vacuum case is 0.001 and the AE frequency is lower as the energy of the EP population decreases. Toroidal Alfvén eigenmodes with f = 80–120 kHz and elliptical AE between f = 120–350 kHz are triggered between the middle-outer plasma region (r/a > 0.5). The AE stability improves in the simulations with finite β equilibria and three period configurations with respect to the vacuum case with two periods because the continuum gaps are slender, leading to a higher threshold of the EP β, above 0.03 for the AEs triggered by the helical mode families. Helical effects are not strong enough to destabilize Helical Alfvén eigenmodes, the AEs with the largest growth rates are triggered by the n=1 and n=2 toroidal families.This work was supported by NIFS07KLPH004 and the Project 2019-T1/AMB-13648 founded by the Comunidad de Madrid.Publicad

New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation

The selection and discovery of new crystalline forms is a longstanding issue in solid-state chemistry of critical importance because of the effect molecular packing arrangement exerts on materials properties. Polymer-induced heteronucleation has recently been developed as a powerful approach to discover and control the production of crystal modifications based on the insoluble polymer heteronucleant added to the crystallization solution. The selective nucleation and discovery of new crystal forms of the well-studied pharmaceuticals flurbiprofen (FBP) and sulindac (SUL) has been achieved utilizing this approach. For the first time, FBP form III was produced in bulk quantities and its crystal structure was also determined. Furthermore, a novel 3:2 FBP:H 2 O phase was discovered that nucleates selectively from only a few polymers. Crystallization of SUL in the presence of insoluble polymers facilitated the growth of form I single crystals suitable for structure determination. Additionally, a new SUL polymorph (form IV) was discovered by this method. The crystal forms of FBP and SUL are characterized by Raman and FTIR spectroscopies, X-ray diffraction, and differential scanning calorimetry. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96: 2978–2986, 2007Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/57336/1/20954_ftp.pd

Pseudopolymorphic transitions of niclosamide monitored by Raman spectroscopy

Niclosamide suffers pseudopolymorphic transformations when exposed to different ambient conditions, which can lead to changes in its bioavailability. In this study, the kinetics of the pseudopolymorphic transitions of niclosamide crystals are characterized. FT-Raman spectroscopy is used to quantify the anhydrate and hydrate forms of niclosamide crystals, mostly because of its high sensitivity to the strong intermolecular interactions present in these systems. The samples are exposed to well-characterized relative humidity (RH) conditions during different periods of time and both water diffusion and polymorphic changes are monitored from the corresponding changes observed in the vibrational spectra. Both hydration and dehydration were found to be single-step processes, with a half-life time of ca. 142 and 63 h, respectively, at 24 °C. Copyright © 2008 John Wiley & Sons, Ltd

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Polymer-Induced Heteronucleation for the Discovery of New Extended Solids This work was supported by the U.S. Department of Energy and the Beckman Foundation. A.L.G. was a fellow of the NSF-sponsored IGERT program for Molecularly Designed Electronic, Photonic, and Nanostructured Materials at the University of Michigan.

No AbstractPeer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/50643/1/2615_ftp.pd